Description medicine: disodium edetate (Dinatrii aethylendiamintetraacetas)

Trilon (Dinatrii aethylendiamintetraacetas).

Synonyms: Trilon B, EDTA, Calsol, Dinatriumedetat, Endrate, Irgalon , Kalex, Prochelate, Questrex, Sequestrene, Sequestrol, Sodium edetate, Tetracemindinatriumi, Titriplex, Trilon B, Tyclarosol, Versene and others.

White crystalline powder, soluble in water, practically insoluble in alcohol and ether.

Disodium EDTA (Na 2 EDTA) applies, as well as calcium and tetatsin pentatsin, a chelating group.

Capable of forming complexes with various cations, including calcium ions. This enables the use of EDTA in diseases accompanied by excessive deposition of calcium salts in the body, while pathological ossification of the skeleton, arthritis with salt deposition, the deposition of calcium in the muscles, kidneys, the walls of the veins, scleroderma and others. Sometimes it is used to treat some forms of ectopic arrhythmias, especially arising in connection with an overdose of cardiac glycosides.

When used for therapeutic purposes must be considered that the therapeutic effect without the side effects occurs at a slow introduction into the bloodstream of the drug; in these conditions the interaction with serum calcium is slow and calcium content in serum is not significantly reduced, since the loss is compensated by the mobilization of calcium from the tissue, in particular bone and excessive deposits in the organs. With the rapid introduction of the drug physiological mechanisms do not have time to eliminate a decrease in serum calcium levels and may develop acute tetany.

EDTA, due to the ability to bind calcium ions, is also used as an anticoagulant in the preservation of blood.

The main indication for the use of EDTA are diseases with the phenomena of calcification: dermatomyositis, scleroderma, myositis ossificans.

For therapeutic purposes, use of EDTA solution intravenously. Dilute 5% EDTA solution in isotonic sodium chloride solution or 5% glucose solution.

Administered at 8 - 12 drops per minute. Adults and children over 10 years old are introduced to 10 ml of 5% EDTA solution, diluted in 200 mL of solvent; children up to 10 years - 5 ml 5% EDTA solution, diluted in 100 ml of solvent.

The course of treatment consists of 15 injections: administered in cycles of 5 days each day at 7-day intervals (a total of 3 cycles per course). The courses of treatment repeated at 4 - 6 months.

During treatment it is necessary to monitor the content of calcium and phosphorus in the blood and daily urine. Diet during treatment should contain a reduced amount of calcium.

With the introduction of the drug into a vein, and sometimes there is a burning sensation that can spread throughout the body and persist for 1 - 2 hours after the end of infusion.

With the rapid introduction can develop tetany; In these cases, the drug administration should be discontinued.

EDTA is contraindicated in hemophilia, reduced blood clotting, hypocalcemia, kidney and liver.

Product: 5% solution in ampoules of 5 or 10 ml (Solutio Dinatrii aethylendiamintetraacetatis 5% Pro injectionibus) in a package of 10 vials.

Storage: List B.